SCHEMBL13487273

SCHEMBL13487273

CC1(C)c2ccccc2-c2c(-c3c4ccccc4c(-c4ccccn4)c4ccc(-c5ccc6ccccc6c5)cc34)cccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 2/20 0.38
TSHR P16473 1/20 0.38
KLF5 Q13887 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HTR2C P28335 1/20 0.36
SIRT2 Q8IXJ6 2/20 0.35
PDK2 Q15119 1/20 0.34
NPC1 O15118 2/20 0.33
DCTPP1 Q9H773 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
ABL1 P00519 1/20 0.33
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487322 0.94 KDM4E (0.35) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487170 0.90 HTR2C (0.42) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487275 0.90 SIRT2 (0.34) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487102 0.90 PDK2 (0.36) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487353 0.90 PDK2 (0.41) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487278 0.90 SIRT2 (0.37) KDM4ESIRT2PDK2ABL1CYP2C9
SCHEMBL13487274 0.89 CYP17A1 (0.33) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487281 0.89 MAPK9 (0.36) KDM4ECYP2C9PIM1CYP1A2CYP17A1
SCHEMBL13488050 0.88 PDK2 (0.40) KDM4EMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL13487684 0.87 KDM4E (0.38) KDM4EMAPTSMN1; SMN2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
EP-2108689-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 KDM4E 3671/4885MAPT 2219/4885SMN1; SMN2 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.